Cancer Res Treat.  2025 Jul;57(3):883-890. 10.4143/crt.2024.781.

Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea

• Koh Y
• Yoon SS
• Kim K
• Lee JJ
• Jung SH
• Yoon SE
• Park SS
• Park Y
• Yoon S
• Min CK

• KMID: 2569674
• DOI: http://doi.org/10.4143/crt.2024.781

Abstract

Purpose
Daratumumab is a novel, first-in-class monoclonal antibody approved for use as monotherapy and in combination with other treatments for patients with multiple myeloma (MM). The aim of this observational study was to evaluate the effectiveness and safety of daratumumab in real-world clinical practice.
Materials and Methods
This observational multicenter study collected data from patients with MM treated in Korea between June 1, 2018, and February 28, 2022.
Results
A total of 125 patients with a diagnosis of MM were included and followed until discontinuation or completion of 52 weeks’ follow-up. The median age was 67 years, and 97.6% of patients received more than three prior lines of therapy. The overall response rate was 52.5% (95% confidence interval [CI], 43.2 to 61.8), and a very good partial response was observed in 19.5% of patients (95% CI, 12.8 to 27.8). Of the patients who achieved a partial or higher response (52.5%), the median time to first response was 2.4 months (95% CI, 1.8 to 3.4), and the median time from start of daratumumab treatment until progressive disease was 4.1 months (95% CI, 2.9 to 5.1). Fever (24.0%) was the most frequently recorded adverse event (AE), while anemia (8.8%) and neutropenia (8.0%) were the most frequently observed grade 3-4 AEs. Overall, no unexpected safety signals were observed.
Conclusion
In a rapidly evolving treatment landscape, this analysis provides insight into the real-world outcomes for patients with MM receiving daratumumab in Korea and reveals that real-world outcomes were improved over results demonstrated in a clinical trial setting.

Keyword

Daratumumab; Immunotherapy; Korea; Multiple myeloma; Real-world

Reference

References

1. Noll JE, Williams SA, Tong CM, Wang H, Quach JM, Purton LE, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2014; 99:163–71.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–49.

3. Jung KW, Won YJ, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2019. Cancer Res Treat. 2019; 51:431–7.

4. Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022; 9:e670–7.

5. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97:1086–107.

6. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387:1551–60.

7. Nadeem O, Tai YT, Anderson KC. Immunotherapeutic and targeted approaches in multiple myeloma. Immunotargets Ther. 2020; 9:201–15.

8. Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016; 9:51.

9. Daratumumab [Internet]. U.S. Food and Drug Administration; c2016 [cited 2023 Oct 2]. Available from: www.fda.gov/drugs/resources-information-approved-drugs/daratumumab-darzalex.

10. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:1319–31.

11. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:754–66.

12. Yadav S, Gundeti S, Bhave A, Deb U, Dixit J, Mishra K. Role of daratumumab in the frontline management of multiple myeloma: a narrative review. Expert Rev Hematol. 2023; 16:743–60.

13. FDA approves daratumumab for transplant-eligible multiple myeloma [Internet]. U.S. Food and Drug Administration; c2019 [cited 2023 Nov 1]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma.

14. Byun JM, Yoon SS, Koh Y, Kim I, Jo J, Park H, et al. Daratumumab monotherapy in heavily pretreated Asian patients with relapsed and refractory multiple myeloma: a real-world experience. Anticancer Res. 2019; 39:5165–70.

15. Use effective drugs in early multiple myeloma to prevent relapse [Internet]. Korean Doctor’s Weekly Co. Ltd.; c2021 [cited 2023 Dec 4]. Available from: https://www.koreabiomed.com/news/articleView.html?idxno=11176.

16. Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8:109.

17. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017; 376:1311–20.

18. Burns L, Roux NL, Kalesnik-Orszulak R, Christian J, Hukkelhoven M, Rockhold F, et al. Real-world evidence for regulatory decision-making: guidance from around the world. Clin Ther. 2022; 44:420–37.

19. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15:e538–48.

20. Salomon-Perzynski A, Walter-Croneck A, Usnarska-Zubkiewicz L, Dytfeld D, Zielinska P, Wojciechowska M, et al. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Adv Med Sci. 2019; 64:349–55.

21. Park SS, Byun JM, Yoon SS, Kim K, Jung SH, Lee JJ, et al. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. Br J Haematol. 2021; 193:101–12.

22. Markovic U, Romano A, Del Fabro V, Bellofiore C, Bulla A, Parisi MS, et al. Daratumumab as single agent in relapsed/refractory myeloma patients: a retrospective real-life survey. Front Oncol. 2021; 11:624405.

23. Bertamini L, Bertuglia G, Oliva S. Beyond clinical trials in patients with multiple myeloma: a critical review of real-world results. Front Oncol. 2022; 12:844779.

24. Maouche N, Srinivasan A, Leary H, Collings F, Tseu B, Vallance GD, et al. Daratumumab monotherapy for heavily pre-treated and refractory myeloma: results from a UK Multicentre Real World Cohort. J Oncol Pharm Pract. 2023; 29:299–304.

25. Szabo AG, Klausen TW, Levring MB, Preiss B, Helleberg C, Breinholt MF, et al. The real-world outcomes of multiple myeloma patients treated with daratumumab. PLoS One. 2021; 16:e0258487.

26. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018; 35:1763–74.

27. Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019; 133:1534–9.